Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit : a randomized clinical trial
ABSTRACT: Introduction Critically ill patients can develop hyperglycaemia even if they do not have diabetes. Intensive insulin therapy decreases morbidity and mortality rates in patients in a surgical intensive care unit (ICU) and decreases morbidity in patients in a medical ICU. The effect of this...
- Autores:
-
Toro Escobar, Juan Manuel
Arango Toro, Clara María
De La Rosa, Gisela Del Carmen
Donado, Jorge Hernando
Restrepo, Álvaro Humberto
Quintero, Álvaro Mauricio
González, Luis Gabriel
Saldarriaga, Nora Elena
Bedoya, Marisol
Velásquez, Jorge Byron
Valencia, Juan Carlos
Aleman, Pablo Henrique
Martin Vásquez, Esdras
Chavarriaga, Juan Carlos
Yepes, Andrés
Pulido, William
Cadavid, Carlos Alberto
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2008
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/31677
- Acceso en línea:
- https://hdl.handle.net/10495/31677
- Palabra clave:
- Glucemia
Blood Glucose
Cuidados Críticos
Critical Care
Índice Glucémico
Glycemic Index
Unidades de Cuidados Intensivos
Intensive Care Units
Hospitalización
Hospitalization
Insulina - sangre
Insulin - blood
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
Summary: | ABSTRACT: Introduction Critically ill patients can develop hyperglycaemia even if they do not have diabetes. Intensive insulin therapy decreases morbidity and mortality rates in patients in a surgical intensive care unit (ICU) and decreases morbidity in patients in a medical ICU. The effect of this therapy on patients in a mixed medical/surgical ICU is unknown. Our goal was to assess whether the effect of intensive insulin therapy, compared with standard therapy, decreases morbidity and mortality in patients hospitalised in a mixed ICU. Methods This is a prospective, randomised, non-blinded, singlecentre clinical trial in a medical/surgical ICU. Patients were randomly assigned to receive either intensive insulin therapy to maintain glucose levels between 80 and 110 mg/dl (4.4 to 6.1 mmol/l) or standard insulin therapy to maintain glucose levels between 180 and 200 mg/dl (10 and 11.1 mmol/l). The primary end point was mortality at 28 days. Results Over a period of 30 months, 504 patients were enrolled. The 28-day mortality rate was 32.4% (81 of 250) in the standard insulin therapy group and 36.6% (93 of 254) in the intensive insulin therapy group (Relative Risk [RR]: 1.1; 95% confidence interval [CI]: 0.85 to 1.42). The ICU mortality in the standard insulin therapy group was 31.2% (78 of 250) and 33.1% (84 of 254) in the intensive insulin therapy group (RR: 1.06; 95%CI: 0.82 to 1.36). There was no statistically significant reduction in the rate of ICU-acquired infections: 33.2% in the standard insulin therapy group compared with 27.17% in the intensive insulin therapy group (RR: 0.82; 95%CI: 0.63 to 1.07). The rate of hypoglycaemia (≤ 40 mg/dl) was 1.7% in the standard insulin therapy group and 8.5% in the intensive insulin therapy group (RR: 5.04; 95% CI: 1.20 to 21.12). Conclusions IIT used to maintain glucose levels within normal limits did not reduce morbidity or mortality of patients admitted to a mixed medical/surgical ICU. Furthermore, this therapy increased the risk of hypoglycaemia. Trial Registration clinicaltrials.gov Identifiers: 4374-04-13031; 094-2 in 000966421 |
---|